Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors
Endocrine Abstracts · 04.03.2026
DOI: 10.1530/endoabs.116.t9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 04.03.2026. Verfasst von MD und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
MD, Hope,, T. A., Haydu,, P. L., Hendifar,, M. A., Mohamed,, M. A., Soares,, M. H., Shergill,, M. A., Fisher,, M. G., O'Dwyer,, M. P. J., MD, Meyerhardt,, M. J., O'Reilly,, M. E., & Padda,, M. S. K. (2026). Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors. Endocrine Abstracts. https://doi.org/10.1530/endoabs.116.t9
Vancouver
MD, Hope, TA, Haydu, PL, Hendifar, MA, Mohamed, MA, Soares, MH, et al. Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors. Endocrine Abstracts. 2026. doi:10.1530/endoabs.116.t9
BibTeX
@article{MD2026,
author = {MD and Hope,, Thomas A and Haydu,, PhD Lauren and Hendifar,, MD Andrew and Mohamed,, MD Amr and Soares,, MD Heloisa and Shergill,, MD Ardaman and Fisher,, MD George and O'Dwyer,, MD Peter J and MD and Meyerhardt,, MPH Jeffrey and O'Reilly,, MD Eileen and Padda,, MD Sukhmani K},
title = {Alliance A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor-Positive Bronchial Neuroendocrine Tumors},
journal = {Endocrine Abstracts},
year = {2026},
doi = {10.1530/endoabs.116.t9}
}
EUVIMED